Baardman, T.

patient study lefradafiban infarct size treatment platelet /iiia receptor level infarction group infarct event trial monitoring value artery heart placebo ischemic recovery episode ischemic episodes table result inhibition angina glycoprotein characteristic fibrinogen therapy peak st level investigator fibrinogen receptor occupancy syndrome analysis blood occupancy thrombolytic therapy safety platelet aggregation aggregation fradafiban thrombolytic study drug outcome percutaneou ischemic area incidence baseline increase streptokinase st trend protein c-reactive intervention disease concentration artery disease hospital inhibitor heparin complication grade blocker association 48 hours death serum lefradafiban 20 mg substudy treatment groups circulation t.i.d st monitoring gusto-i number plasma lefradafiban 30 mg netherland